IART — INTEGRA LIFESCIENCES HOLDINGS CORP

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 917520 ·
Last close
$16.65
Market Cap
$1.29B
52W High
$20.49
52W Low
$10.38
ADV30
1,061,337
Next earnings
2026-10-29
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 418,761,000 219,744,000 19,285,000 4,482,000 3,563,490,000 214,415,000 2,520,113,000
Mar 2026 391,918,000 216,982,000 11,470,000 -4,617,000 3,577,726,000 236,809,000 2,535,320,000
Dec 2025 434,925,000 220,865,000 23,040,000 -1,704,000 3,602,001,000 235,048,000 2,558,538,000
Sep 2025 402,062,000 206,991,000 11,761,000 -5,404,000 3,646,452,000 232,186,000 2,608,878,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$85,327,000
Investing CF
$-108,626,000
Financing CF
$21,576,000
CapEx
$-73,727,000
Dividends Paid
Buybacks
$-2,471,000
EPS Diluted TTM
$-0.09
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$423,306,000
Inventory
$492,005,000
Receivables
$267,188,000
ST Investments
$59,669,000
EBIT TTM
$91,678,000
Pretax Income TTM
$-179,000
Interest Exp TTM
$91,857,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,647,666,048
EBITDA
$316,918,016
Free Cash Flow
$94,402,000
Enterprise Value
$3,070,946,304
Total Cash
$274,084,000
Total Debt
$2,050,118,016
Shares Out
77,772,506
Trailing EPS
$-0.09
Book Value
$13.39
ROE
-0.7%
ROA
2.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,635,245,000 17,995,000 -516,474,000 3,602,001,000 2,558,538,000 50,384,000
Dec 2024 1,610,527,000 28,411,000 -6,944,000 4,037,424,000 2,492,144,000 129,382,000
Dec 2023 1,541,573,000 111,526,000 67,741,000 3,781,988,000 2,194,104,000 139,955,000
Dec 2022 1,557,666,000 238,920,000 180,550,000 3,889,758,000 2,085,355,000 264,469,000

TTM Snapshot

Revenues TTM
$1,535,307,000
NetIncome TTM
$101,946,000
OpCashFlow TTM
$0
Assets (Latest)
$4,037,424,000
Forward EPS
$2.61

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.50 · spot: $16.65 · call volume: 26 · put volume: 7
Expected Move to 2026-09-18: ±$3.88 (23.27%) — implied range $12.77$20.52 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AORT ARTIVION, INC. $1.30B $26.83
CDRE Cadre Holdings, Inc. $1.32B $30.83
TNDM TANDEM DIABETES CARE INC $1.34B $19.50
KMTS KESTRA MEDICAL TECHNOLOGIES, LTD. $1.34B $22.83
CNMD CONMED Corp $1.39B $46.30

News headlines (Yahoo Finance, 1h cache)

Why Integra LifeSciences (IART) Trimmed Its 2026 Outlook After Returning to Profitability
2026-08-02 14:08 · Yahoo
IART Q2 Deep Dive: Flat Revenue, Margin Pressure, and Operational Realignment Shape Outlook
2026-08-01 16:43 · Yahoo
Why Integra LifeSciences (IART) Shares Are Sliding Today
2026-07-30 10:13 · Yahoo
Zacks.com featured highlights include Bassett Furniture, Aveanna Healthcare and Integra LifeSciences
2026-07-30 08:08 · Yahoo
3 Stocks Showing Breakout Potential Ahead of August
2026-07-29 19:00 · Yahoo
Integra LifeSciences Holdings Corporation Q2 2026 Earnings Call Summary
2026-07-29 17:35 · Yahoo
Integra LifeSciences Q2 Earnings Call Highlights
2026-07-29 15:04 · Yahoo
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-07-29 14:30 · Yahoo
Integra LifeSciences (IART) Q2 Earnings Top Estimates
2026-07-29 11:30 · Yahoo
Integra LifeSciences’s (NASDAQ:IART) Q2 CY2026 Earnings Results: Revenue In Line With Expectations
2026-07-29 10:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.